01—Abstract
Summary
Summary of the 10-K filed March 25, 2015. Cited figures are marked; the original filing is the authoritative source.
Leidos Holdings, Inc. reported fiscal 2015 (ended January 30, 2015) revenues of $5.06 billiona, down 12% from $5.76 billion in fiscal 2014, and swung to an operating loss of $214 million from operating income of $163 million the prior year.
The loss was driven primarily by $486 millionb of goodwill impairment charges in the Health and Engineering segment, along with $41 million of intangible asset impairments and a $40 million tangible asset impairment tied to the Plainfield renewable energy plant. Net loss was $323 million, or $(4.36) per diluted share, compared with net income of $164 million the prior year. The company states that about 79% of total revenues came from U.S. Government contracts, with the Department of Defense representing approximately 67%.
The National Security Solutions segment remained the larger contributor, with revenues of $3.59 billionc (down 11%) and operating income of $286 million. Health and Engineering revenues fell 14% to $1.49 billion and posted an operating loss of $472 million. Total backlog declined to $7.8 billion from $9.3 billion, and net bookings were approximately $3.6 billion versus $4.9 billion a year earlier.
Cash and cash equivalents ended the year at $443 milliond, and operating cash flow from continuing operations rose to $396 million from $191 million. The company paid $95 million in dividends, repurchased $215 million of stock, and retired $175 million of debt. The filing also discloses that Leidos agreed on March 24, 2015 to sell its Plainfield biomass plant, a transaction that is partially seller-financed.
The company additionally notes a pending $44 million arbitral award against the Greek government that was annulled by an Athens appeals court, and a $123 million cumulative loss recorded on that contract. Management stated that its existing cash, operating cash flows and $500 million revolving facility are sufficient for at least the next 12 months.
02—Key points
Key Highlights
- Revenues were $5.06 billion in fiscal 2015, down 12% from $5.76 billion, with National Security Solutions down 11% and Health and Engineering down 14%.
- Operating loss of $214 million compared with operating income of $163 million in fiscal 2014, primarily due to $486 million of goodwill impairment charges and $81 million of asset impairment charges.
- Net loss of $323 million, or $(4.36) per diluted share, versus net income of $164 million in fiscal 2014.
- Total backlog fell to $7.8 billion from $9.3 billion, and net bookings were approximately $3.6 billion versus $4.9 billion the prior year.
- Approximately 79% of total revenues came from U.S. Government contracts, with the DoD accounting for approximately 67%.
- Operating cash flow from continuing operations increased to $396 million from $191 million, and cash ended the year at $443 million.
- Agreed in March 2015 to sell the Plainfield biomass plant, which the company had acquired through a foreclosure in fiscal 2014; the transaction is partially seller-financed.
03—One dollar
Follow one dollar
For each $1.00 of revenue in FY2015, Leidos Holdings lost $0.07.
- Revenue$4.69B100.0%
- Cost of revenue−$4.07B86.8%
- Gross profit$621.0M13.2%
- Operating costs−$812.0M17.3%
- Operating income−$191.0M4.1%
- Interest, other & tax−$132.0M2.8%
- Net income−$323.0M6.9%
04—Financials
Financial Highlights
Figures from 10-KFY2015filed March 25, 2015Financial Statements
FY2015 against FY2014
| Line item | FY2015FY2014 | Change |
|---|---|---|
| Revenue | $4.69B$5.75B | −18.5% |
| Cost of Revenue | $4.07B$4.99B | −18.5% |
| Gross Profit | $621.00M$763.00M | −18.6% |
| R&D Expenses | $37.00M$45.00M | −17.8% |
| SG&A Expenses | $280.00M$440.00M | −36.4% |
| Operating Income | -$191.00M$163.00M | −217.2% |
| Interest Expense | $71.00M$82.00M | −13.4% |
| Net Income | -$323.00M$161.00M | −300.6% |
| EPS (Basic) | $-4.51$1.94 | −332.5% |
| EPS (Diluted) | $-4.51$1.94 | −332.5% |
| Shares Outstanding (Basic) | 74.00M83.00M | −10.8% |
| Shares Outstanding (Diluted) | 74.00M83.00M | −10.8% |
05—Questions
Frequently Asked Questions
Why did Leidos report an operating loss in fiscal 2015?
The company recorded $486 million of goodwill impairment charges in its Health Solutions and Engineering reporting units during the second quarter, after declines in forecasted revenue and delayed award decisions. It also recorded $41 million of intangible asset impairments and a $40 million impairment on the Plainfield plant's tangible assets, which together drove the operating loss of $214 million.
How did the company's segments perform?
National Security Solutions revenues fell 11% to $3.59 billion, with operating income of $286 million, down 2%. Health and Engineering revenues fell 14% to $1.49 billion and reported an operating loss of $472 million, compared with operating income of $20 million the prior year. Corporate and Other operating loss narrowed to $28 million from $149 million.
What drove the decline in revenue?
The filing attributes the National Security Solutions decline primarily to the drawdown of overseas U.S. military forces ($320 million) and the ramp-down of the Joint Logistics Integration program ($82 million), along with sequestration and budget cuts. Health and Engineering revenue fell mainly due to lower hospital electronic health record implementations ($82 million) and the completion of an international Army support contract in security products ($39 million).
What is the status of the Greek government contract and the Plainfield plant?
The company holds a $44 million arbitral award against the Hellenic Republic of Greece, which the Athens Court of Appeals annulled in June 2014; Leidos appealed to the Supreme Court of Greece in January 2015 and continues enforcement in U.S. District Court, and the outcomes are described as uncertain. The company has recorded $123 million of cumulative losses on the contract. For Plainfield, a definitive agreement to sell the plant was signed in March 2015, with completion expected in the first half of the next fiscal year.
06—Continue